fda compounding semaglutide warning letters september 2025 GLP-1 Compounding: When Innovation May Mean Liability fda warning letters glp-1 compounded

They reduce hunger

Although Ozempic, Mounjaro, and Rybelsus are not FDA-approved for obesity treatment, they are included in the analysis due to the high number of patients with an obesity diagnosis using these products compared to other FDA-approved Type 2 diabetes GLP-1 agonists

6), and the Guizhou Association for Science and Technology 2025XZQYXM-01-03

A doctor might prescribe bupropion SR for weight loss if they think the medications appetite and craving effects could benefit a person, especially someone who also has depression or is trying to quit smoking

Many patients report feeling full faster and having reduced cravings while on GLP-1 agonists

Liver Relief and Digestive Comfort Modern diets high in refined carbohydrates and hidden fats can overload the liver, leading to non-alcoholic fatty liver disease (NAFLD)